Collegium Announces $50 Million Accelerated Share Repurchase Program

manilatimes.net · 2026-08-13

STOUGHTON, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions, today announced that it has entered into an Accelerated Share Repurchase ('ASR') agreement with Jefferies LLC to repurchase $50 million of the Company’s common stock. Collegium will execute the ASR as part of the $150 million share repurchase program authorized by its Board of Directors in July 2025. Upon completion of this ASR, Collegium will have $100 million remaining under the program.

TickrTrends take: Collegium's announcement of a $50 million accelerated share repurchase program represents a use of capital that can support per-share metrics, which aligns with TickrTrends' current undervalued assessment of the Healthcare sector company. Share repurchases reduce the outstanding share count, a factor that can influence earnings per share calculations and other per-share valuation ratios that investors monitor. For valuation-focused readers tracking COLL, the execution and timing of this buyback program may provide relevant context for understanding changes in per-share financial measures in upcoming reporting periods.

Read the full story at manilatimes.net →